As Health 2.0 approaches, healthcare companies plan to demonstrate the utility of their products and platforms. Health 2.0 will tentatively take place on 17th of September at the Silicon Valley. Seven data-centric healthcare companies would participate in the event to showcase the utility of their technologies. The companies hope to demonstrate the relevance of their technologies for industry stakeholders. It would be crucial for these companies to address the needs of consumers, IT vendors, and payers. Furthermore, data-driven healthcare is likely to become the central theme of discussions and demonstrations at the event.
Following a Cause-Effect Method
Several researchers agree to the utility of data in generating improved outcomes within healthcare. Furthermore, researchers also concur with the idea of using social determinants to gauge healthcare parameters. It is worthwhile to mention that the healthcare fraternity is following a result-oriented approach. This propensity has led to the development distinct pathways for getting desired healthcare outcomes.
Growing Focus on Addressing Mental Health Issues
Data, when utilized outside of clinical practices, has helped individuals in drawing health-related patterns. This has prompted the healthcare industry to develop core modules for data usage within healthcare. Furthermore, mental health has become a matter of concern across the healthcare industry. Availability of data has played a vital role in including mental health in mainstream medicine. Healthcare practitioners have combined data related to social determinants to study their impact on mental health. A number of healthcare organizations have improved their understanding of mental health issues in the masses.
Nascent Company Practices
Several companies are focusing on studying real-world scenarios to improve on their healthcare practices. These companies analyze data outside of the clinical domain to understand the needs and concerns of the masses. This is likely to foster effectiveness, safety, and trust across the healthcare setup. Moreover, populations that remain ignored during clinical trials can also be covered through this practice.